Acute Bronchiolitis Clinical Trial
Official title:
Comparison of High Flow Nasal Cannula and Standard Face Mask Oxygen Therapy in Children With Moderate and Severe Bronchiolitis; a Randomized Controlled Trial
Verified date | February 2021 |
Source | Ege University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study aims to compare the efficacy of two different oxygenation methods on decrease respiratory rate, heart rate, and clinical respiratory score in children with moderate to severe bronchiolitis requiring oxygen therapy. 1. Standard face mask oxygen therapy (St-FMOT) 2. High-flow nasal cannula oxygen therapy (HFNCOT)
Status | Completed |
Enrollment | 87 |
Est. completion date | March 10, 2020 |
Est. primary completion date | March 10, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 1 Month to 24 Months |
Eligibility | Inclusion Criteria: - Children aged between 1-24 months applied with moderate and severe bronchiolitis requiring supplemental oxygen were eligible for the study. - The severity of bronchiolitis was assessed according to the clinical respiratory score (CRS) of Liu et al. (5). The patients with CRS =5 were included. - Peripheral oxyhemoglobin saturation is < 92%. Exclusion criteria: - Children admitted to the ICU for urgent invasive mechanical ventilation; - those who received standard oxygen therapy (SOT) or HFNCOT at other facilities before arrival; - those with an underlying medical condition (such as congenital heart disease, chronic lung disease, neuromuscular disease, metabolic disease, or immunocompromised); - those who had a craniofacial malformation, an upper airway obstruction, pneumothorax, or nasal trauma, and missing parental consent or a refused permission of the participant. |
Country | Name | City | State |
---|---|---|---|
Turkey | Ege University Medical Faculty | Izmir | Select A State |
Lead Sponsor | Collaborator |
---|---|
Ege University |
Turkey,
Beggs S, Wong ZH, Kaul S, Ogden KJ, Walters JA. High-flow nasal cannula therapy for infants with bronchiolitis. Cochrane Database Syst Rev. 2014 Jan 20;(1):CD009609. doi: 10.1002/14651858.CD009609.pub2. Review. — View Citation
Bressan S, Balzani M, Krauss B, Pettenazzo A, Zanconato S, Baraldi E. High-flow nasal cannula oxygen for bronchiolitis in a pediatric ward: a pilot study. Eur J Pediatr. 2013 Dec;172(12):1649-56. doi: 10.1007/s00431-013-2094-4. Epub 2013 Jul 31. — View Citation
Da Dalt L, Bressan S, Martinolli F, Perilongo G, Baraldi E. Treatment of bronchiolitis: state of the art. Early Hum Dev. 2013 Jun;89 Suppl 1:S31-6. doi: 10.1016/S0378-3782(13)70011-2. Review. — View Citation
Franklin D, Babl FE, Schlapbach LJ, Oakley E, Craig S, Neutze J, Furyk J, Fraser JF, Jones M, Whitty JA, Dalziel SR, Schibler A. A Randomized Trial of High-Flow Oxygen Therapy in Infants with Bronchiolitis. N Engl J Med. 2018 Mar 22;378(12):1121-1131. doi — View Citation
Franklin D, Dalziel S, Schlapbach LJ, Babl FE, Oakley E, Craig SS, Furyk JS, Neutze J, Sinn K, Whitty JA, Gibbons K, Fraser J, Schibler A; PARIS and PREDICT. Early high flow nasal cannula therapy in bronchiolitis, a prospective randomised control trial (p — View Citation
Liu G, Fan C, Wu H. High-flow nasal cannula therapies for respiratory management in pediatric patients. Minerva Pediatr. 2018 Oct;70(5):488-492. doi: 10.23736/S0026-4946.17.04781-8. Epub 2017 Mar 27. Review. — View Citation
Mace AO, Gibbons J, Schultz A, Knight G, Martin AC. Humidified high-flow nasal cannula oxygen for bronchiolitis: should we go with the flow? Arch Dis Child. 2018 Mar;103(3):303. doi: 10.1136/archdischild-2017-313950. Epub 2017 Sep 13. — View Citation
Milési C, Boubal M, Jacquot A, Baleine J, Durand S, Odena MP, Cambonie G. High-flow nasal cannula: recommendations for daily practice in pediatrics. Ann Intensive Care. 2014 Sep 30;4:29. doi: 10.1186/s13613-014-0029-5. eCollection 2014. Review. — View Citation
Milési C, Pierre AF, Deho A, Pouyau R, Liet JM, Guillot C, Guilbert AS, Rambaud J, Millet A, Afanetti M, Guichoux J, Genuini M, Mansir T, Bergounioux J, Michel F, Marcoux MO, Baleine J, Durand S, Durand P, Dauger S, Javouhey E, Leteurtre S, Brissaud O, Re — View Citation
Pham TM, O'Malley L, Mayfield S, Martin S, Schibler A. The effect of high flow nasal cannula therapy on the work of breathing in infants with bronchiolitis. Pediatr Pulmonol. 2015 Jul;50(7):713-20. doi: 10.1002/ppul.23060. Epub 2014 May 21. — View Citation
Schibler A, Franklin D. Respiratory support for children in the emergency department. J Paediatr Child Health. 2016 Feb;52(2):192-6. doi: 10.1111/jpc.13078. Review. — View Citation
Testa G, Iodice F, Ricci Z, Vitale V, De Razza F, Haiberger R, Iacoella C, Conti G, Cogo P. Comparative evaluation of high-flow nasal cannula and conventional oxygen therapy in paediatric cardiac surgical patients: a randomized controlled trial. Interact — View Citation
* Note: There are 12 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time Taken to Reach the Normal Range for Heart Rate (Per-protocol Analysis) | The time that heart rate takes into the normal range for age between the groups (Per-protocol analysis). | through study completion, an average of 96 hours | |
Primary | Time Taken to Reach the Normal Range for Respiratory Rate (Per-protocol Analysis) | The time that the respiratory rate takes into the normal range for age between the groups (Per-protocol analysis). | through study completion, an average of 96 hours | |
Primary | Time Taken to Regress A Lower Clinical Respiratory Score (Per-protocol Analysis) | Unabbreviated scale title: Clinical Respiratory Score (Per-protocol analysis). The time that takes from severe bronchiolitis (9-12 points) to moderate bronchiolitis (5-8 points) or from moderate bronchiolitis (5-8 points) to mild bronchiolitis (0-4 points) between the groups. Higher scores mean a worse outcome. The score ranges from 0-12. | through study completion, an average of 96 hours | |
Secondary | Heart Rate (Intention-to-treat Analysis) | Any differences in the time any recorded changes in heart rate from randomization to the patients' discharge within the groups and between the groups (Intention-to-treat analysis). | Baseline, 1,2,4,12,24,48,72 and 96 hours | |
Secondary | Heart Rate (Per-protocol Analysis) | Any differences in the time any recorded changes in heart rate from randomization to the patients' discharge within the groups and between the groups (Per-protocol analysis). | Baseline, 1,2,4,12,24,48,72 and 96 hours | |
Secondary | Respiratory Rate (Intention-to-treat Analysis) | Any differences in the time any recorded changes in respiratory rate from randomization to the patients' discharge within the groups and between the groups (Intention-to-treat analysis). | Baseline, 1,2,4,12,24,48,72 and 96 hours | |
Secondary | Respiratory Rate (Per-protocol Analysis) | Any differences in the time any recorded changes in respiratory rate from randomization to the patients' discharge within the groups and between the groups (Per-protocol analysis). | Baseline, 1,2,4,12,24,48,72 and 96 hours | |
Secondary | Clinical Respiratory Score (Intention-to-treat Analysis) | Unabbreviated scale title: Clinical Respiratory Score (Intention-to-treat analysis) Any differences in the time any recorded changes in the clinical respiratory score from randomization to the patients' discharge within the groups and between the groups.
This clinical respiratory score includes respiratory rate, retraction, dyspnea/consciousness status, and wheezing. The severity of parameters is scored 0 to 3 points, and the patients with a clinical respiratory score of 0-4 points were defined as mild, moderate (5-8 points), and severe (9-12 point) bronchiolitis. Higher scores mean a worse outcome. The score ranges from 0-12. |
Baseline, 1,2,4,12,24,48,72 and 96 hours | |
Secondary | Clinical Respiratory Score (Per-protocol Analysis) | Unabbreviated scale title: Clinical Respiratory Score (Per-protocol analysis). Any differences in the time any recorded changes in the clinical respiratory score from randomization to the patients' discharge within the groups and between the groups. This clinical respiratory score includes respiratory rate, retraction, dyspnea/consciousness status, and wheezing. The severity of parameters is scored 0 to 3 points, and the patients with a clinical respiratory score of 0-4 points were defined as mild, moderate (5-8 points), and severe (9-12 point) bronchiolitis. Higher scores mean a worse outcome. The score ranges from 0-12. | Baseline, 1,2,4,12,24,48,72 and 96 hours | |
Secondary | Oxygen Requirement (Intention-to-treat Analysis) | The total duration of oxygen therapy (Intention-to-treat analysis). | through study completion, an average of 168 hours | |
Secondary | Oxygen Requirement (Per-protocol Analysis) | The total duration of oxygen therapy (Per-protocol analysis). | through study completion, an average of 168 hours | |
Secondary | Length of Hospital Stay (Intention-to-treat Analysis) | The time from randomization to the patient's discharge (Intention-to-treat analysis). | through study completion, an average of 168 hours | |
Secondary | Length of Hospital Stay (Per-protocol Analysis) | The time from randomization to the patient's discharge (Per-protocol analysis). | through study completion, an average of 168 hours | |
Secondary | Treatment Failure at 4 Hours (Intention-to-treat Analysis) | The number of treatment failures at 4 hours in each study arm (Intention-to-treat analysis). | 4 hours | |
Secondary | Pediatric Intensive Care Unit Admission (Intention-to-treat Analysis). | The number of participants admitted to the intensive care unit for invasive mechanical ventilation (Intention-to-treat analysis). | through study completion, an average of 168 hours | |
Secondary | Adverse Events of Therapy (Intention-to-treat Analysis) | The number of participants with any adverse events in therapy groups (Intention-to-treat analysis). | through study completion, an average of 168 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01469845 -
The SABRE Trial of Hypertonic Saline in Acute Bronchiolitis
|
Phase 3 | |
Completed |
NCT02962505 -
Continuous Regional Analysis Device for Neonate Lung
|
||
Recruiting |
NCT02984046 -
Acute Bronchiolitis and Severity Markers: Interest in Protein CC16
|
N/A | |
Completed |
NCT01875757 -
Effect of Supplementation With Vitamin D on the Acute Bronchitis Prevention During the First Year of Life
|
Phase 3 | |
Completed |
NCT01871857 -
7% Hypertonic Saline for Acute Bronchiolitis
|
Phase 4 | |
Completed |
NCT06139029 -
Comparison of 3% Normal Saline Nebulization Versus Steroid Nebulization in the Treatment of Bronchiolitis
|
Early Phase 1 | |
Not yet recruiting |
NCT03915197 -
Acute Bronchiolitis in Infants and Allergic Asthma
|
N/A | |
Completed |
NCT03171142 -
Effect of Heliox on RSV Bronchiolitis
|
Phase 3 | |
Not yet recruiting |
NCT06441162 -
Efficacy Of Combined Nebulized Hypertonic Saline and Chest Percussion Therapy in Acute Viral Bronchiolitis
|
Phase 4 | |
Recruiting |
NCT02093715 -
FeNO and Cytokines in Respiratory Syncytial Virus (RSV) and Non RSV Bronchiolitis in Relation to Future Asthma
|
N/A | |
Not yet recruiting |
NCT03880903 -
Hypertonic Saline Inhalation in Acute Bronchiolitis
|
Phase 4 | |
Completed |
NCT04748159 -
Effects of Prone Positioning on Vital Parameters in Infants With Acute Bronchiolitis
|
N/A | |
Active, not recruiting |
NCT04613180 -
Evaluation of the Effectiveness of Montelukast in Children With Recurrent Obstructive Bronchitis
|
Phase 4 | |
Recruiting |
NCT06321133 -
High Flow Nasal Cannula Weaning in Acute Bronchiolitis
|
N/A | |
Completed |
NCT02029040 -
Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis
|
N/A | |
Recruiting |
NCT03753802 -
Evaluation of the Effects of Respiratory Physiotherapy in Infants With Moderate Acute Bronchiolitis
|
N/A | |
Withdrawn |
NCT01660867 -
Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis in the Emergency Department
|
Phase 4 |